Skip to main content
Uncategorized

Inbiomotion appoints Dr. David L. Lacey to its Board of Directors

By 29 de January de 2013November 18th, 2020No Comments
< Back to news
David L. Lacey. © Inbiomotion.
 29.01.2013

Inbiomotion appoints Dr. David L. Lacey to its Board of Directors

Inbiomotion SL, a company focused on the development of a specific biomarker for the prediction of bone metastasis, has strengthened its board of directors with the appointment of Dr. David L. Lacey, former Senior Vice President and Head of Discovery Research at Amgen. Dr Lacey has over 30 years experience of basic and clinical research experience in in hematology, oncology, inflammation, metabolic disorders and neuroscience.


Inbiomotion is a spin-off from the Institute for Research in Biomedicine (IRB Barcelona) and the Institució Catalana de Recerca i Estudis Avançats (ICREA). Located at the Barcelona Science Park and founded by Dr. Roger Gomis, – group leader of IRB Barcelona’s Growth Control and Cancer Metastasis Laboratory– in July 2012 the company closed a € 2 million Series A financing led by Ysios Capital.